Global Glaucoma Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

List of Tables

The global demand for Glaucoma Treatment Market is presumed to reach the market size of nearly USD 12.1 BN by 2032 from USD 7.66 BN in 2023 with a CAGR of 5.21% under the study period 2024 - 2032.

The treatment of glaucoma involves a range of medical and surgical interventions to manage and control the progression of eye conditions. In glaucoma, the optic nerve is damaged, which is often linked to elevated intraocular pressure (IOP). As a leading cause of irreversible blindness, there is currently no cure for glaucoma. However, treatment strategies are focused on preventing additional damage to the optic nerve and preserving vision.

MARKET DYNAMICS

The Glaucoma treatment market is propelled by various factors responding to the increasing global prevalence of glaucoma, particularly among the aging population. Technological advancements in treatment options, including laser therapies and minimally invasive glaucoma surgeries (MIGS), contribute to the expansion of effective interventions. Rising awareness and early detection efforts emphasize the demand for diverse treatment options to address varying patient needs. The preference for minimally invasive procedures, such as MIGS, influences patient choices, offering reduced recovery times and improved outcomes. Increased healthcare expenditure, government initiatives supporting eye health, and collaborations among industry stakeholders drive innovation in glaucoma treatment. The competitive market landscape and continuous product development contribute to the introduction of new and improved treatment modalities. Additionally, expanding access to eye care services and educational initiatives further fuel the demand for glaucoma treatments.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of glaucoma treatment. The growth and trends of glaucoma treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the glaucoma treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

Prostaglandin Analogs (PGAs)
Alpha Agonnist
Beta Borkers
Cholinergic
Carbonic Anhydrase Inhibitom
Combined Medications

By Indication

Angle Clasura Glaucoma (ACG)
Open Angle Glaucuma (OAC)
Secondary Glaucoma
Congenital Glaucoma
Other Indications

By Sales Channel

Hospital Pharmacies
Retail Pharmacies
Online Sales

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Glaucoma Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Glaucoma Treatment market include Novartile AG, Pfizer Inc, Merck & Co. Ine, Bausch & Lomb Inc., Allergan Plc, Perrigo Plc, Teva Pharmaceutical Industries Ltd, Akorn Inc, Mobius Therapeutics LLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112113373

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . GLAUCOMA TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product Type
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Sales Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL GLAUCOMA TREATMENT MARKET ANALYSIS BY PRODUCT TYPE

5.1 Overview by Product Type
5.2 Historical and Forecast Data
5.3 Analysis by Product Type
5.4 Prostaglandin Analogs (PGAs) Historic and Forecast Sales by Regions
5.5 Alpha Agonnist Historic and Forecast Sales by Regions
5.6 Beta Borkers Historic and Forecast Sales by Regions
5.7 Cholinergic Historic and Forecast Sales by Regions
5.8 Carbonic Anhydrase Inhibitom Historic and Forecast Sales by Regions
5.9 Combined Medications Historic and Forecast Sales by Regions

6 . GLOBAL GLAUCOMA TREATMENT MARKET ANALYSIS BY INDICATION

6.1 Overview by Indication
6.2 Historical and Forecast Data
6.3 Analysis by Indication
6.4 Angle Clasura Glaucoma (ACG) Historic and Forecast Sales by Regions
6.5 Open Angle Glaucuma (OAC) Historic and Forecast Sales by Regions
6.6 Secondary Glaucoma Historic and Forecast Sales by Regions
6.7 Congenital Glaucoma Historic and Forecast Sales by Regions
6.8 Other Indications Historic and Forecast Sales by Regions

7 . GLOBAL GLAUCOMA TREATMENT MARKET ANALYSIS BY SALES CHANNEL

7.1 Overview by Sales Channel
7.2 Historical and Forecast Data
7.3 Analysis by Sales Channel
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Online Sales Historic and Forecast Sales by Regions

8 . GLOBAL GLAUCOMA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE GLAUCOMA TREATMENT COMPANIES

9.1. Glaucoma Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF GLAUCOMA TREATMENT INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Novartile AG
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Pfizer Inc
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Merck & Co. Ine
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Bausch & Lomb Inc.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Allergan Plc
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Perrigo Plc
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Teva Pharmaceutical Industries Ltd
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Akorn Inc
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Mobius Therapeutics LLC
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies